solute carrier family 43 member 1Genealiases: LAT3 · PB39 · POV1 · R00504
Q-omics provides the consensus-scored SLC43A1 profile across patient tissues and cancer cell-line models. SLC43A1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SLC43A1 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, SLC43A1 RNA expression shows 18,291 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, KIRP, and TGCT as cancer lineages where SLC43A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC43A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC43A1 survival associations across molecular data types. SLC43A1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC43A1 RNA expression–survival associations across cancer types. High SLC43A1 expression shows unfavorable associations in COAD, KIRP, ACC and THCA, but favorable associations in UCEC and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for SLC43A1 RNA expression.
This table summarizes SLC43A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC43A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC43A1 shows lower tumor expression in KIRP, KIRC, THCA, BLCA and LUSC and higher tumor expression in COAD. The KIRP box plot shows higher SLC43A1 RNA expression in normal versus tumor tissue (log2 FC = −2.895, t-test p < 0.001).
This table shows molecular features associated with SLC43A1 in patient tissues and cancer cell lines. In patient samples, SLC43A1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC43A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
